Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Pneumologie (Stuttgart, Germany)
|
January 15, 2010
[Bronchial aspergillosis]
I Dobbertin, G Friedel, R Jaki, et al.
Physical Review. E
|
January 20, 2018
Unifying different interpretations of the nonlinear response in glass-forming liquids
P Gadige, S Albert, M Michl, et al.
Oncology
|
January 10, 2014
Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors
M Michl, A R Haug, T F Jakobs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2010
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
V Heinemann, D Di Gioia, U Vehling-Kaiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)
J W Holch, S Held, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
ESMO Open
|
May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
M Boukovala, D P Modest, I Ricard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Pneumologie (Stuttgart, Germany)
|
January 15, 2010
[Bronchial aspergillosis]
I Dobbertin, G Friedel, R Jaki, et al.
Physical Review. E
|
January 20, 2018
Unifying different interpretations of the nonlinear response in glass-forming liquids
P Gadige, S Albert, M Michl, et al.
Oncology
|
January 10, 2014
Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors
M Michl, A R Haug, T F Jakobs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2010
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
V Heinemann, D Di Gioia, U Vehling-Kaiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)
J W Holch, S Held, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
ESMO Open
|
May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
M Boukovala, D P Modest, I Ricard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Page
of 3